A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

Paul Manning Biography and Net Worth

Director of Acumen Pharmaceuticals

Paul B. Manning is Chairman of the Board of the Company. Mr. Manning is the Chairman and Chief Executive Officer of PBM Capital Group, LLC, a private equity investment firm in the business of investing in healthcare and life-science related companies, which he founded in 2010. Prior to that, Mr. Manning founded PBM Products in 1997, a producer of infant formula and baby food, which was sold to Perrigo Corporation in 2010. Mr. Manning is a director of various private companies. Within the past five years, Mr. Manning previously served on the Board of Directors of Dova Pharmaceuticals, Inc., Perrigo Corporation, Concordia Healthcare Corp. and AveXis, Inc. Mr. Manning received a B.S. in microbiology from the University of Massachusetts. Our Board of Directors believes that Mr. Manning should serve as a director based upon his over 30 years of managerial and operational experience in the healthcare industry and as an investor in healthcare related companies.

What is Paul B. Manning's net worth?: The estimated net worth of Paul B. Manning is at least $52.35 million as of November 17th, 2023. Mr. Manning owns 16,566,667 shares of Acumen Pharmaceuticals stock worth more than $52,350,668 as of April 18th. This net worth approximation does not reflect any other assets that Mr. Manning may own. Learn More about Paul B. Manning's net worth.
How do I contact Paul B. Manning?: The corporate mailing address for Mr. Manning and other Acumen Pharmaceuticals executives is , , . Acumen Pharmaceuticals can also be reached via phone at 434-297-1000 and via email at [email protected]. Learn More on Paul B. Manning's contact information.
Has Paul B. Manning been buying or selling shares of Acumen Pharmaceuticals?: Paul B. Manning has not been actively trading shares of Acumen Pharmaceuticals within the last three months. Most recently, on Tuesday, July 6th, Paul B. Manning bought 312,500 shares of Acumen Pharmaceuticals stock. The stock was acquired at an average cost of $16.00 per share, with a total value of $5,000,000.00. Learn More on Paul B. Manning's trading history.
Who are Acumen Pharmaceuticals' active insiders?: Acumen Pharmaceuticals' insider roster includes Marc Benioff (CEO), Nathan Fountain (Director), Paul Manning (Director), and John Stalfort, III (Director). Learn More on Acumen Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Acumen Pharmaceuticals?: During the last year, Acumen Pharmaceuticals insiders bought shares 1 times. They purchased a total of 5,161,290 shares worth more than $39,999,997.50. During the last year, insiders at the sold shares 5 times. They sold a total of 73,157 shares worth more than $382,384.76. The most recent insider tranaction occured on January, 19th when CEO Daniel Joseph Oconnell sold 15,200 shares worth more than $52,744.00. Insiders at Acumen Pharmaceuticals own 7.5% of the company. Learn More about insider trades at Acumen Pharmaceuticals.
Information on this page was last updated on 1/19/2024.

Paul B. Manning Insider Trading History at Acumen Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/6/2021	Buy	312,500	$16.00	$5,000,000.00

Paul B. Manning Buying and Selling Activity at Acumen Pharmaceuticals

Acumen Pharmaceuticals Company Overview

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Today's Range

Now: $3.16

$3.11

$3.48

50 Day Range

MA: $3.86

$3.09

$4.64

2 Week Range

Now: $3.16

$1.81

$11.31

Volume

636,210 shs

Average Volume

381,640 shs

Market Capitalization

$189.85 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.08

SHOCKING Crypto Leak…

From Crypto 101 Media | Ad